A Sun1, L D Durocher-Allen2, P M Ellis3,4, Y C Ung5, J R Goffin3, K Ramchandar6, G Darling7. 1. Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON. 2. Program in Evidence-Based Care, McMaster University, Hamilton, ON. 3. Medical Oncology, Juravinski Cancer Centre, Hamilton, ON. 4. Department of Oncology, McMaster University, Hamilton, ON. 5. Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON. 6. Radiation Oncology, Thunder Bay Regional Health Sciences Centre Regional Cancer Care, Thunder Bay, ON. 7. Thoracic Surgery, Toronto General Hospital, Toronto, ON.
Abstract
Background: Patients with limited-stage (ls) or extensive-stage (es) small-cell lung cancer (sclc) are commonly given platinum-based chemotherapy as first-line treatment. Standard chemotherapy for patients with ls sclc includes a platinum agent such as cisplatin combined with the non-platinum agent etoposide. The objective of the present systematic review was to investigate the efficacy of adding radiotherapy to chemotherapy in patients with es sclc and to determine the appropriate timing, dose, and schedule of chemotherapy or radiation for patients with sclc. Methods: The medline and embase databases were searched for randomized controlled trials (rcts) comparing treatment with radiotherapy plus chemotherapy against treatment with chemotherapy alone in patients with es sclc. Identified rcts were also included if they compared various timings, doses, and schedules of treatment for patients with es sclc or ls sclc. Results: Sixty-four rcts were included. In patients with ls sclc, overall survival was greatest with platinum-etoposide compared with other chemotherapy regimens. In patients with es sclc, overall survival was greatest with chemotherapy containing platinum-irinotecan than with chemotherapy containing platinum-etoposide (hazard ratio: 0.84; 95% confidence interval: 0.74 to 0.95; p = 0.006). The addition of radiation to chemotherapy for patients with es sclc showed mixed results. There was no conclusive evidence that the timing, dose, or schedule of thoracic radiation affected treatment outcomes in sclc. Conclusions: In patients with ls sclc, cisplatin-etoposide plus radiotherapy should remain the standard therapy. In patients with es sclc, the evidence is insufficient to recommend the addition of radiotherapy to chemotherapy as standard practice to improve overall survival. However, on a case-by-case basis, radiotherapy might be added to reduce local recurrence. The most commonly used chemotherapy is platinum-etoposide; however, platinum-irinotecan can be considered.
Background: Patients with limited-stage (ls) or extensive-stage (es) small-cell lung cancer (sclc) are commonly given platinum-based chemotherapy as first-line treatment. Standard chemotherapy for patients with ls sclc includes a platinum agent such as cisplatin combined with the non-platinum agent etoposide. The objective of the present systematic review was to investigate the efficacy of adding radiotherapy to chemotherapy in patients with es sclc and to determine the appropriate timing, dose, and schedule of chemotherapy or radiation for patients with sclc. Methods: The medline and embase databases were searched for randomized controlled trials (rcts) comparing treatment with radiotherapy plus chemotherapy against treatment with chemotherapy alone in patients with es sclc. Identified rcts were also included if they compared various timings, doses, and schedules of treatment for patients with es sclc or ls sclc. Results: Sixty-four rcts were included. In patients with ls sclc, overall survival was greatest with platinum-etoposide compared with other chemotherapy regimens. In patients with es sclc, overall survival was greatest with chemotherapy containing platinum-irinotecan than with chemotherapy containing platinum-etoposide (hazard ratio: 0.84; 95% confidence interval: 0.74 to 0.95; p = 0.006). The addition of radiation to chemotherapy for patients with es sclc showed mixed results. There was no conclusive evidence that the timing, dose, or schedule of thoracic radiation affected treatment outcomes in sclc. Conclusions: In patients with ls sclc, cisplatin-etoposide plus radiotherapy should remain the standard therapy. In patients with es sclc, the evidence is insufficient to recommend the addition of radiotherapy to chemotherapy as standard practice to improve overall survival. However, on a case-by-case basis, radiotherapy might be added to reduce local recurrence. The most commonly used chemotherapy is platinum-etoposide; however, platinum-irinotecan can be considered.
Authors: Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Reidulv Hatlevoll; Ragnar Dahle; Nils Boye; Mari Wang; Tor Vigander; Jan Vilsvik; Eva Skovlund; Einar Hannisdal; Steinar Aamdal Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: D Mavroudis; E Papadakis; M Veslemes; X Tsiafaki; J Stavrakakis; C Kouroussis; S Kakolyris; E Bania; J Jordanoglou; M Agelidou; J Vlachonicolis; V Georgoulias Journal: Ann Oncol Date: 2001-04 Impact factor: 32.976
Authors: Edward F McClay; Jeff Bogart; James E Herndon; Dee Watson; Lisa Evans; Steven L Seagren; Mark R Green Journal: Am J Clin Oncol Date: 2005-02 Impact factor: 2.339
Authors: B Jeremic; Y Shibamoto; N Nikolic; B Milicic; S Milisavljevic; A Dagovic; J Aleksandrovic; G Radosavljevic-Asic Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Stephen G Spiro; Lindsay E James; Robin M Rudd; Colin W Trask; Jeffrey S Tobias; Michael Snee; David Gilligan; Philip A Murray; Mary Carmen Ruiz de Elvira; Katy M O'Donnell; Nicole H Gower; Peter G Harper; Allan K Hackshaw Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Paul L Schaefer; Randolph S Marks; Michelle R Mahoney; Jeff A Sloan; Mitchell D Bauman; Henry D Tazelaar; John W Kugler; James A Mailliard; Larry P Ebbert; Martin Wiesenfeld Journal: Am J Clin Oncol Date: 2003-06 Impact factor: 2.339
Authors: Charles M Rudin; Ravi Salgia; Xiaofei Wang; Lydia D Hodgson; Gregory A Masters; Mark Green; Everett E Vokes Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: H Ueoka; K Kiura; M Tabata; H Kamei; K Gemba; K Sakae; Y Hiraki; S Hiraki; Y Segawa; M Harada Journal: Cancer Date: 1998-07-15 Impact factor: 6.860
Authors: Corinne Faivre-Finn; Michael Snee; Linda Ashcroft; Wiebke Appel; Fabrice Barlesi; Adityanarayan Bhatnagar; Andrea Bezjak; Felipe Cardenal; Pierre Fournel; Susan Harden; Cecile Le Pechoux; Rhona McMenemin; Nazia Mohammed; Mary O'Brien; Jason Pantarotto; Veerle Surmont; Jan P Van Meerbeeck; Penella J Woll; Paul Lorigan; Fiona Blackhall Journal: Lancet Oncol Date: 2017-06-20 Impact factor: 41.316
Authors: Tiandong Kong; Lu Chen; Xiaoli Zhao; Fangfang Duan; Hanli Zhou; Lei Wang; Danna Liu Journal: Invest New Drugs Date: 2022-07-05 Impact factor: 3.651